Recombinant Human S100A15 His-tag Protein, CF

Recombinant Human S100A15 Protein (Catalog # 11804-SA) binds to Human S100A15 Antibody with an ED50 of <500 ng/mL.

2 μg/lane of Recombinant Human S100A15 Protein (Catalog # 11804-SA) was resolved with SDS-PAGE under reducing (R) condition and visualized by Coomassie® Blue staining, showing bands at 11-13 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human S100A15 His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA.

  Recombinant Human S100A15 (Catalog # 11804-SA) binds to Human S100A15 Antibody with an ED₅₀ of <500 ng/mL.

• Source: E. coli-derived human S100A7A protein
  Ser2 - Gln101, with an N-terminal His tag
• N-terminal Sequence: His
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 11 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 11-13 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 2 weeks, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in Tris with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Reconstitution Instructions: Reconstitute at 250 μg/mL in water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human S100A15 His-tag Protein, CF

• protein S100-A7A
• NICE2
• NICE-2
• S100 calcium binding protein A7A
• S100A15
• S100A7A
• S100A7f
• S100A7L1

Background

S100 calcium‑binding protein A15 (S100A15), also known as koebnerisin, is a small (~11 kDa) member of the S100 family of EF‑hand proteins encoded within the epidermal differentiation complex on chromosome 1q21. S100A15 emerged through primate‑specific gene duplication and is highly homologous (>90% sequence identity) to S100A7 (psoriasin), yet displays distinct regulation, cellular distribution, and biological function (1). S100A15 is predominantly expressed in stratified squamous epithelia, including the skin and mucosal surfaces, and is markedly upregulated in inflammatory skin disorders such as psoriasis, particularly in koebnerized lesions. Functionally, S100A15 acts as an innate immune alarmin and antimicrobial peptide, contributing to epithelial barrier defense and immune cell recruitment during inflammation (2, 3). Unlike many classical S100 proteins, S100A15 exhibits context‑dependent extracellular signaling activity that promotes chemotaxis and cytokine production in immune cells. Extracellular S100A15 functions as a pro‑inflammatory mediator, stimulating leukocyte migration and amplifying local inflammatory responses through receptor pathways that are distinct from those used by its paralog S100A7. While S100A7 signals via the receptor for advanced glycation end products (RAGE), S100A15 primarily acts through a Gi‑protein‑coupled receptor pathway, enabling synergistic yet nonredundant pro‑inflammatory signaling in epithelial tissues (4). This functional divergence allows the S100A7/S100A15 subfamily to fine‑tune immune responses at sites of tissue stress or damage. Beyond inflammatory disease, dysregulated S100A15 expression has been implicated in epithelial carcinogenesis, where it participates in shaping the tumor microenvironment through immune modulation, chemotactic signaling, and epithelial–immune crosstalk. Depending on cellular context, S100A15 may support chronic inflammation that promotes tumor progression or serve as a marker of epithelial immune activation (1, 5). Recombinant human S100A15 is therefore a valuable research tool for studying innate immunity, epithelial barrier biology, inflammatory signaling, alarmin function, and cancer‑associated inflammation, as well as for dissecting functional differences within the closely related S100A7/A15 protein subfamily.

1. Wolf, R. et al. (2010) Amino Acids 41:789.
2. Hattinger, E. et al. (2013) Curr. Opin. Pharmacol. 13:588.
3. Kurpet, K. et al. (2022) Molecules 27:6640.
4. Wolf, R. et al. (2008) J. Immunol. 181:1499.
5. Liang, H. et al. (2023) Front. Immunol. 14:1191645.